Diana L.Calla

Associate

San Francisco + 1.415.875.5723

Connect:

Share

Diana Calla represents companies in litigation and government investigations, primarily in the health care and financial services industries. She has litigated cases involving the False Claims Act, RICO, the Fair Credit Reporting Act, and consumer class actions, among others. She has experience with investigations, motions practice, expert witnesses, and pretrial discovery.

Diana also maintains an active pro bono practice and has worked on matters including an asylum application, a support proceeding in family court, and civil rights litigation. During law school she represented Section 8 tenants in administrative hearings with local housing authorities.

Prior to attending law school Diana worked as a paralegal for the Antitrust Division of the Department of Justice.

Experience

  • HDR Global Trading obtains dismissal with prejudice in 33-count lawsuitJones Day client HDR Global Trading Limited ("HDR"), the Seychelles-incorporated owner and operator of the BitMEX cryptocurrency derivatives trading platform, obtained dismissal with prejudice of a 33-count lawsuit alleging violations of the Commodity Exchange Act, RICO, and various California statutory and common law claims.
  • ICANN obtains advice in highly publicized decision regarding proposed sale of .ORG registryJones Day successfully advised ICANN in conjunction with its highly publicized decision over whether to reject the proposed sale of the .ORG registry on the Internet to a private equity firm that had offered to pay over $1 billion for the registry.
  • Quicken Loans successfully defends against RMBS putback suit in New York State courtJones Day successfully defended Quicken Loans, Inc., a mortgage lender based in Detroit, Michigan, against a suit brought on behalf of investors in a residential mortgage-backed securities ("RMBS") trust in New York state court.
  • Sanofi defends proposed class action alleging conspiracy to raise pricesJones Day is defending Sanofi-Aventis U.S. LLC against a proposed class action alleging that the company conspired with or through pharmacy benefit managers to raise prices for its diabetes drug, Lantus, in violation of federal and state antitrust, consumer protection, fraud, RICO, and employee benefit laws.
  • Celgene resolves False Claims Act case related to alleged off-label promotion of Thalomid® and Revlimid®Jones Day represented Celgene Corporation in a False Claims Act lawsuit related to allegations that Celgene promoted the cancer treatment drugs Thalomid® and Revlimid® for off-label uses prior to their FDA approval for such uses, and paid kickbacks to physicians in order to get them to promote and prescribe those drugs.
  • Atlantic Health System acquires Hackettstown Regional Medical CenterJones Day represented Atlantic Health System in the transfer of ownership of Hackettstown Regional Medical Center from Adventist HealthCare to Atlantic Health System.
    • View All

    September 2018 Commentaries

    Ninth Circuit Clarifies Import of Escobar in False Claims Act Litigation

    January 2018 Commentaries

    Third Circuit Rejects False Claims Act Theory that Anti-Kickback Violations "Taint" All Related Claims

    January 2018 Commentaries

    False Claims Act's "Rigorous" Materiality Standard Enforced by Second Circuit

    November 2017 Commentaries

    Third Circuit Confirms Government Knowledge Can Defeat Scienter and Materiality Requirements for False Claims Act Liability

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.